Global Head of Bioanalysis & Immunogenicity
Sanofi, Ghent, Belgium
Ghent, Oost-Vlaanderen, Belgium
Samuel Pine, PhD (Global Head of Bioanalysis and Immunogenicity, DMPK at Sanofi) is an accomplished drug development expert with a broad background in biotherapeutic, vaccine, and diagnostic R&D and a strong focus in immunogenicity. In his current role he provides leadership and guidance to scientists developing and implementing PK, ADA and biomarker methods for the Sanofi R&D portfolio. He regularly contributes to scientific discussions in the fields of immunogenicity and bioanalysis at international symposia and is an active member of industry working groups from AAPS, EBF and EIP. Prior to Sanofi, Samuel held roles of increasing responsibility at BioAgilytix, Allergan, the Infectious Disease Research Institute, the Fred Hutchinson Cancer Research Center and Chiron/Novartis. He received his bachelor’s degree at the University of California, Santa Cruz and his PhD in Pathobiology from the University of Washington.
Sunday, June 25, 2023
18:30 – 19:30 ET